According to the Research Director of Prostate Cancer UK (the largest prostate patient charity in the UK) a large group of leading physicians recently concluded that the one diagnostic measure that they need, but do not have, is prostate volume – what ProstaMetric measures. The ProstaMetric® device measures Prostate Volume, a key risk factor for diagnosing prostate disease and assessing prostate cancer risk, early in the diagnostic process, at low cost. Physicians believe that it will reduce the number of prostate biopsies/MRI’s by at least half.
For GPs it allows them to determine who should be referred to a specialist improving the quality of their referrals. As one physician noted, ProstaMetric will be “a step up in sophistication for the GP and an improved transition step for the urologist.”
For urologists, prostate volume is clinically significant in the evaluation and management of benign prostatic hyperplasia (BPH), i.e., to assess whether 5-α reductase inhibitor therapy would be effective, etc. Prostate size is also important when using some new treatment technologies and for planning a surgical strategy for removing all or part of the prostate.
Today, Prostate Specific Antigen (PSA) is the principal marker for prostate cancer screening and is used to screen males for prostate cancer beginning at age 45 – 50. Men with a blood serum PSA; 4 ng/ml are referred for prostate biopsy. However, approximately 75% of prostate biopsies (at approximately $1,800/biopsy) are negative, i.e. patients do not have prostate cancer. With approximately 1.1 Million prostate biopsies performed annually, an estimated $1.5B is spent in the U.S. annually on prostate biopsies with negative results.
A number of centers around the world have developed prostate risk calculators with algorithms that combine prostate volume, PSA, DRE results (normal/abnormal), to determine Detectable cancer risk and clinically significant cancer risk. Of these, prostate volume is considered to be one of the most important, if not most important risk factors. Using volume from TRUS or MRI, one major Medical Center in Europe has reduced the number of biopsies by 55%. ProstaMetric will be much more cost effective, and can be done early the diagnostic process before many of the costs of diagnosis have been incurred – lab tests, biopsies, MRI….
BPH, an enlarged prostate, is caused by the growth of the prostate gland. Since the prostate gland surrounds the urethra, the tube that carries urine from the bladder out of the body, as the prostate gets bigger, it may squeeze or partly oclude the urethra often causing problems with urination and chronic urinary retention. In planing for corrective surgery, such as TURP (transurethral resection of prostate), laser ablation, or UroLift, it is helpful for the urologist to know the volume of the prostate to decide which approach will be most effective.
ProstaMetric enables low cost determination of prostate volume early in the diagnostic process, at low cost, and has been shown to be as accurate as transrectal ultrasound (TRUS) in estimating prostate volume.
All contents © Copyright MedicaMetrix, Inc. 2007-2015. All Rights Reserved. All content of this Internet site is owned or controlled by MedicaMetrix, Inc. and is protected by worldwide copyright laws. You may download content only for your personal use for non-commercial purposes, but no modification or further reproduction of the content is permitted. The content may otherwise not be copied or used in any way.
ProstaMetric® and MedicaMetrix® are registered trademarks of MedicaMetrix, Inc. registered in the United States and internationally. The trademarks, service marks, trade names, trade dress and products in this Internet site are protected in the United States and internationally. No use of any of these may be made without the prior, written authorization of MedicaMetrix, Inc., except to identify the products or services of the company